E Bernasconi
[HIV superinfection: myth or reality?]
Vernazza P, Bernasconi E, Hirschel B. [HIV superinfection: myth or reality?]. Schweizerische medizinische Wochenschrift 2000; 130:1101-4.
Aug 8, 2000[HIV superinfection: myth or reality?]
Aug 8, 2000Schweizerische medizinische Wochenschrift 2000; 130:1101-4
Vernazza Pietro, Bernasconi E, Hirschel B
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA : the journal of the American Medical Association 1999; 282:2220-6.
Dec 15, 1999AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Dec 15, 1999JAMA : the journal of the American Medical Association 1999; 282:2220-6
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza Pietro, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9.
Jun 1, 1999Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Jun 1, 1999Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9
Bassetti S, Bernasconi E, Vernazza Pietro, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. The New England journal of medicine 1999; 340:1301-6.
Apr 29, 1999Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Apr 29, 1999The New England journal of medicine 1999; 340:1301-6
Furrer H, Flepp M, Rickenbach M, Vernazza Pietro, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:F71-7.
May 28, 1998A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
May 28, 1998AIDS (London, England) 1998; 12:F71-7
Rutschmann O T, Perrin L H, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H C, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study
Rutschmann O, Yerly S, Perrin L, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antiviral therapy 1998; 3 Suppl 4:65-7.
Jan 1, 1998Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study
Jan 1, 1998Antiviral therapy 1998; 3 Suppl 4:65-7
Rutschmann O T, Yerly S, Perrin L H, Bernasconi E, Bucher H, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B